Compare STKE & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STKE | RNXT |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.3M | 37.4M |
| IPO Year | N/A | 2021 |
| Metric | STKE | RNXT |
|---|---|---|
| Price | $1.31 | $0.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 157.7K | 156.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.60 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,000.00 |
| Revenue This Year | $15.56 | $2,995.35 |
| Revenue Next Year | $44.24 | $219.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $0.70 |
| 52 Week High | $7.75 | $1.45 |
| Indicator | STKE | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 43.07 |
| Support Level | $1.18 | $0.89 |
| Resistance Level | $2.80 | $1.07 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 40.00 | 20.63 |
Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.